Leuprorelin| CAS 53714-56-0|DC Chemicals

Cas No.:	53714-56-0
Chemical Name:	Leuprolide acetate
Synonyms:	Leuprorelin;5-OXOPRO-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHC2H5;[DES-GLY10, DLEU6, PRO9]-LH-RH, ETHYL AMIDE;[DES-GLY10, DLEU6, PRO9]-LUTEINIZING HORMONE-RELEASING HORMONE, ETHYL AMIDE;[DES-GLY10, DLEU 6, PRONHET9];(DES-GLY10,D-LEU6,PRO-NHET9)-GONADOTROPIN-RELEASING HORMONE;(DES-GLY10,D-LEU6,PRO-NHET9)-LHRH;[DES-GLY10, D-LEU6, PRO-NHET9]-LH-RH (HUMAN);(DES-GLY10,D-LEU6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING FACTOR;(DES-GLY10,D-LEU6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING HORMONE;[DES-GLY10, D-LEU6, PRO-NHET9]-LUTEINIZING HORMONE-RELEASING HORMONE HUMAN;DES-GLY10,[P-LEU6]-LH-RH ETHYLAMIDE;GLP-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHET;LEUPROLIDE ACETATE;LEUPROLIDE (HUMAN);LEUPRORELIN ACETATE;LH-RH LEUPROLIDE;PGLU-HIS-TRP-SER-TYR-D-LEU-LEU-ARG-PRO-NHET;[DES-GLY10,DLEU6, PRONHET9] LH-RH LEUPROLIDE;Leuprolide; LHRH ethylamide;5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide;Carcinil;des-Gly10 ethylamide]gonadotropin releasing hormone;Enantone;GLP-HIS-TRP-SER-TYR-DLEU-LEU-ARG-PRO-NHET: GLP-HWSY-DL-LRP-NHET;Leuplin;LEUPROPELIN;Lucrin;nghormone;pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5;Luteinizinghormone-releasing factor (pig),6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-;(D-Leu6,des-Gly-NH210)-LH-RH ethylamide;A43818;D-Leu6-des-Gly10-LH-releasing hormone ethylamide;Des-Gly10-[D-Leu6]-LH-releasing hormone ethylamide;Des-Gly10-[D-Leu6]LH-RHethylamide;1-9-Luteinizinghormone-releasing factor (swine), 6-D-leucine-9-(N-ethyl-L-prolinamide)-;Lupron SR;NSC 377526;1: PN: WO02087616 PAGE: 31 claimed protein;Lupron;Leuprolide acetate salt;Prostap;Lutrate;Onectyl;Enanton;leuprolide-acetate;DSSTox_RID_83201;DSSTox_CID_28935;DSSTox_GSID_49009;MLS000028695;RGLRXNKKBLIBQS-XNHQSDQCSA-N;Tox21_113507;SMR00005894
SMILES:	CC(O)=O.NC(N)=NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2N=CNC=2)NC(=O)[C@H]3NC(=O)CC3)CC4C5=C(C=CC=C5)NC=4)C(=O)N6[C@@H](CCC6)C(=O)NCC
Formula:	C₆₁H₈₈N₁₆O₁₄
M.Wt:	1269.4502
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Leuprolide is an agonist at pituitary GnRH receptors. Target: GnRH receptorLeuprorelin is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. Leuprorelin acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, Leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. [1] By interrupting the normal pulsatile stimulation of, and thus desensitizing, the GnRH receptors, it indirectly downregulates the secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes. [2]

References:

[1]. Plosker GL, Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs.1994 Dec;48(6):930-967. [2]. Leuprorelin

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.